In the Press

Filters
Type
Sectors
Geography
Companies

Sign up for our free
equity research notes

Register
1617 Results
Embed
James Carthew comments on Saba’s IEM stake in Daily Mail online

James Carthew comments on Saba’s IEM stake in Jane Denton’s article: “Honestly, we are as confused as everyone else about the new Saba announcement. “Today, Saba says it has a 29.9 per cent stake – more than it had before the tender – but, it appears to be saying so by press release rather than […]

James Carthew comments on the IEM Saba saga in FT Adviser

James Carthew comments on Saba and IEM in Tara O’Connor’s article: “Maybe it is time to move onto the next phase of this saga. One where a new set of supposedly independent directors are forced to justify their actions and face potential legal repercussions if they don’t act in all shareholders’ best interests.” Read the […]

James Carthew comments on Saba requisition moves in Portfolio Adviser

James Carthew comments on Saba pushing for the IEM board to resign in Patrick Sanders’ article: “Maybe it’s time to move onto the next phase of the saga”, he added. “One where a new set of supposedly independent directors are forced to justify their actions and face potential legal repercussions if they don’t act in […]

James Carthew comments in Investment Week on Saba moves to replace IEM board

James Carthew comments on Saba’s latest announcement in Linus Uhlig’s article: “We are as confused as everyone else about the new Saba announcement. The board told us ‘it appears from an analysis of the elections that Saba has elected to tender the majority, if not all, of its position’. Today, Saba says it has a […]

Biotech trusts top performance charts in February
Matthew Read comments on the EWIT board’s difficult position in Investment Week

Matthew Read comments on EWIT board challenges in Linus Uhlig’s article: “It is clear that the board has been placed in an exceptionally difficult position: trying to act for all shareholders while a significant minority investor seeks to railroad others and impose its own agenda in what looks like an attempt to gather assets under […]

Biotech trusts top performance charts in February
Matthew Read and James Carthew comment on the IEM tender in Portfolio Adviser

Matthew Read comments on Saba and the IEM tender in Patrick Sanders’ article: “Saba forced through its agenda by overriding the wishes of independent shareholders in what appeared to be a scramble to corral assets under management, only to throw in the towel at the final hurdle by tendering the bulk – if not all […]

Matthew Read comments on the IEM tender result in Investment Week

Matthew Read comments on the IEM tender in Linus Uhlig’s article: “Viewed one way, this whole saga looks like a futile exercise. Saba forced through its agenda by overriding the wishes of independent shareholders in what appeared to be a scramble to corral assets under management, only to throw in the towel at the final […]

Biotech trusts top performance charts in February
James Carthew comments on Visma and HGT in The Observer

James Carthew comments on the delayed Visma IPO in Barney Macintyre’s article: “[The IPO] would have been a really big realisation. They would have looked to try and do it at a premium to the carrying value. It would have been wonderful,” Read the article here

James Carthew comments on IEM tender pass in Portfolio Adviser

James Carthew comments on the low turnout for IEM’s tender in Patrick Sanders’ article: “surprisingly low turnout for such an important question..That suggests to us that Saba did not vote,” Read the article here

James Carthew comments on IEM tender result in Investment Week

James Carthew comments on IEM’s tender and low turnout in Linus Uhlig’s article: “It feels inevitable to us that there will be some shares that were not tendered and the fate of those shareholders and the rump trust is, as yet, unknown. Will Saba have retained a big enough stake to control its future?” Read […]

Biotech trusts top performance charts in February